此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Impact of an Arginine-containing Toothpaste on the Subgingival Microbiota in Patients in Supportive Periodontal Care

2026年9月4日 更新者:Sukirth M Ganesan, BDS, PhD

This study aims to see how a toothpaste with arginine affects bacteria below the gum line compared to a regular fluoride toothpaste. It focuses on people with gum disease who are already getting ongoing dental care.

The main questions it aims to answer are:

  • How does an arginine toothpaste affect the bacteria below the gumline?
  • How does a fluoride toothpaste affect the bacteria below the gumline?

Participants will:

  • Use fluoride toothpaste or arginine toothpaste twice daily for 6 months
  • After receiving the toothpaste at the baseline visit, subjects will visit the clinic at 3 months and 6 months for additional data collection.

研究概览

研究类型

介入性

注册 (估计的)

108

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Iowa
      • Iowa City、Iowa、美国、52242
        • The University of Iowa College of Dentistry

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Understands and is willing to sign an Informed Consent, approved by the local Ethics Committee.
  • Female or male, ages 18-95 years old (inclusive)
  • Systemically healthy.
  • Presence of at least three evaluable teeth in each quadrant.
  • Moderate gingival inflammation, with at least a 10% of bleeding on probing (BOP) will be required together with moderate level of plaque.
  • No Grade 3 Tooth Mobility
  • Treated stage II or III periodontitis patients, whose active treatment has finalized more than 6 months before. Stage II - Interdental clinical attachment level (CAL) at the site of greatest loss equal to 3 to 4 millimeters with maximum probing depth of less than or equal to 5 millimeters. Stage III - Interdental CAL at the site of greatest loss greater than equal to 5 millimeters, probing depth (PD) greater than or equal to 6 millimeters, and radiographic vertical bone loss
  • Enrolled in a periodontal maintenance treatment program
  • No orthodontic banding (no permanent retainers, no orthodontic appliances (i.e., no removable plastic/metal retainer) or removable prosthesis (no removable partial and/or full denture).
  • Subjects willing to participate and comply with the requirements of the study.
  • Subjects that brush their teeth regularly (once or twice daily).
  • Able to travel to and attend 4 research study visits over the span of the next 6 months.
  • Able to independently provide consent for oneself.
  • Fluent in reading, comprehending, and speaking English without assistance from a translator.
  • If a patient is using prevident, they must be willing to stop using it.

Exclusion Criteria:

  • Untreated or uncontrolled periodontitis or advanced (advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive alveolar bone loss)
  • Antibiotics intake within the previous month.
  • Pregnant women and/or breastfeeding women
  • Any adverse medical history (controlled and uncontrolled diabetes, osteoporosis, immunosuppression…) or long-term medication (chemotherapy and immunosuppression treatment; pharmacological treatment associated with gingival overgrowth such as the use of phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, amlodipine, verapamil, cyclosporine) influencing gingival conditions.
  • Conditions which require antibiotic prophylaxis (infectious endocarditis, cardiac valve prosthesis…).
  • Not willing to comply with the study protocol recommendation and visit schedule.
  • Current smokers or those using tobacco or vaping products.
  • Five (5) or more decayed, untreated dental sites (cavities) and/or any dental condition requiring urgent dental care
  • Currently participating in another clinical research study now and/or within the past month.
  • Has a history of allergies to oral care or personal care consumer products or their ingredients
  • Has an existing medical condition that prohibits eating or drinking for periods up to 4 hours.
  • Any ongoing medical condition that makes a subject unsuitable for enrollment-or any new diagnosis that arises during the study that makes the subject unsuitable to continue-may lead to exclusion, as determined by the Principal Investigator on a case by case basis. Conditions that may result in exclusion include, but are not limited to:

    1. Recent myocardial infarction
    2. Recent cerebrovascular accident
    3. Recent placement of a cardiac valvular prosthesis
    4. Severe liver dysfunction
    5. Known or suspected current malignancy
    6. New antibiotic use
    7. Note: The Principal Investigator will review all available information about the subject and make decisions regarding both enrollment and/or continued participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Arginine Toothpaste Use for Two Times Per Day for 6 Months
Participants will use arginine toothpaste twice daily (morning and evening) for 6 months. Sterile paper will be used to collect plaque from below the gum line at baseline, 3 months, and 6 months.
其他名称:
  • Tom's of Maine
有源比较器:Fluoride Toothpaste Use for Two Times Per Day for 6 Months
Participants will use fluoride toothpaste twice daily (morning and evening) for 6 months. Sterile paper will be used to collect plaque from below the gum line at baseline, 3 months, and 6 months.
其他名称:
  • 高露洁腔保护

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Changes in the abundance of microbial strains will be evaluated in all enrolled participants by collecting subgingival dental plaque, followed by genomic profiling of the samples.
大体时间:Baseline, 3 months, and 6 months
Baseline, 3 months, and 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sukirth Ganesan, BDS,PhD,MPH、University of Iowa

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月5日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2026年8月4日

首先提交符合 QC 标准的

2026年8月4日

首次发布 (实际的)

2026年8月10日

研究记录更新

最后更新发布 (实际的)

2026年9月10日

上次提交的符合 QC 标准的更新

2026年9月4日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 202411492

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅